
Keywords: Antituberculosis drug; (-)-Deoxypergularinine; Synergy; Rifampicin; Isoniazid(-)-DPG, (-)-deoxypergularinine; TB, tuberculosis; MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis; MGIT, mycobacteria growth indicator